Match Document Document Title
6924305 Diazocine derivatives and their use as tryptase inhibitors  
Compounds of the formula I, in which B1, B2, R1, R2, R6, R7, K1 and K2 are as defined in the description are novel effective tryp-tase inhibitors.
6916831 Flavone acetic acid analogs and methods of use thereof  
Compounds are described having a structure according to Formula I or Formula II: wherein: X is selected from the group consisting of O, NH, and S; Y is selected from the group consisting of O...
6908732 Compounds and methods for regulating cell differentiation  
The present invention makes available methods and reagents for inhibiting cell growth or promoting cell differentiation comprising contacting the cell with a differeguline in a sufficient amount to...
6906098 Mixed steroidal 1,2,4,5-tetraoxane compounds and methods of making and using thereof  
Disclosed herein are mixed steroidal tetraoxanes having the following structural formula 1 wherein n is 0, 1, 2, or 3; R is H; ethanoyl, propanoyl, or benzoyl; R1 is H, methyl, ethyl, or...
6903129 D-proline prodrugs  
The invention relates to compounds of formulas wherein R 1 and R 2 are independently from each other lower alkoxy, lower alkenyloxy, benzyloxy, hydroxy, —OCH(CH 3 )OC(O)-lower alkyl or...
6903116 Methods of treating cancer using a heat shock factor activity inhibitor  
A disease treatment is provided by controlling the expression of a protein induced by a heat shock factor. The novel compound benzo-1,3-dioxole provides an inhibitor of HSF activity or an...
6903131 3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists  
Disclosed are compounds of the formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the treatment of chemokine-mediated diseases such as acute and...
6900227 Benzodioxole derivatives  
The present invention relates to compounds of the general formula and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases such...
6897211 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors  
The present invention relates to the dibenzoazulene compounds represented by formula I as well as to their pharmaceutical preparations for the inhibition of tumor necrosis factor alpha (TNF-α) and...
6894072 Compounds as NS3-serine protease inhibitors of hepatitis C virus  
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses...
6890928 Aromatic sulfone hydroxamic acids and their use as protease inhibitors  
This invention is directed to aromatic sulfone hydroxamic acids (including hydroxamates) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix...
6887888 Soluble compositions of triphenylethylene antiestrogens  
Aqueous compositions of nonsteroidal triphenylethylene antiestrogens for pharmaceutical use comprising as a solubility enhancing agent a pharmaceutically acceptable mono- or dicarboxylic acid...
6887893 Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia  
Certain cyclooxygenase-2 inhibitors are useful for the treatment and prevention of tumors and tumor-related disorders and cachexia.
6881733 Serotonergic benzofurans  
The present invention provides serotonergic benzofurans of Formula (I): where A, R, R 1 , R 2 , R 3 , and R 4 are as described in the specification.
6878733 Formulations for pharmaceutical agents ionizable as free acids or free bases  
The present invention features formulations of indolinones which compounds are ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the...
6872735 LFA-1 antagonist compounds  
The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R 1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte...
6867230 Hygromycin A derivatives  
This invention relates to compounds of the formula and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 2 , R 3 and R 10 are as defined herein. The...
6864270 Iron binding agents  
Composition, article of manufacture for and method of treating malaria in a human having an infestation of Plasmodium protozoans are described. The method comprises administering a...
6858227 Vitamin E conjugates  
Vitamin E conjugates, methods for their preparation, and compositions that include the conjugates. The vitamin E conjugates include a tocopherol moiety covalently coupled through a linker moiety to...
6852752 Urea compounds, compositions and methods of use and preparation  
Novel hydroxamic acid compounds are disclosed. These hydroxamates inhibit peptide deformylase (PDF), an enzyme present in prokaryotes and are therefore useful as antimicrobials and antibiotics....
6852713 Lactam derivatives and methods of their use  
Lactam derivatives of the general formula are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed.
6849639 Integrin inhibitors and their methods of use  
The invention comprises novel compounds that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated diseases, in particular, diseases or conditions mediated...
6849622 Aliphatic nitrogenous five-membered ring compounds  
The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: wherein A represents —CH 2 — or —S—, R 1 ...
6846817 Nicotine receptor ligands  
The invention provides nicotine receptor agonists of formula I: wherein R 1 , x, y, and n have any of the values given in the specification, or a pharmaceutically acceptable salt thereof, as...
6844336 4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity  
This invention describes the new 4-fluoroalkyl-2H-benzopyrans of general formula I, in which Z is a straight-chain or branched-chain alkyl group with up to 5 carbon atoms that is...
6844346 Chromogenic substrates of sialidase and methods of making and using the same  
The subject invention discloses materials and methods for the design, synthesis, and biochemical evaluation of chromogenic substrate compounds for sialidases of bacterial, viral, protozoa, and...
6841576 Anti-hypertensive composition and methods of treatment  
Pharmaceutical compositions for the treatment of hypertension comprising an effective anti-hypertensive amount of at least one compound in association with a pharmaceutically acceptable,...
6838478 Amino acid derivatives and their use as thrombin inhibitors  
There is provided compounds of formula I, wherein R 1 , R 2 , R 3 , R x , Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like...
6838477 Lactacystin analogs  
Described herein are compounds related to lactacystin and lactacystin β-lactone, pharmaceutical compositions containing the compounds, and methods of use.
6838479 Amidine inhibitors of serine proteases  
Inhibitors of serine proteases are provided having formula (I) wherein X, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. In particular, the compounds bind to factor VIIa, tissue...
6835742 Synergistic effect of amlodipine and atorvastatin on cholesterol crystal formation inhibition and aortic endothelial cell nitric oxide release  
The combination of the antihypertensive calcium channel blocker amlodipine and lipid-lowering agent atorvastatin inhibits free cholesterol crystallization in atherosclerotic-like membranes. In...
6835726 Pyrimidine derivatives  
Compounds and compositions are provided which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives.
6828318 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission  
Compounds of formula (1): wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from hydrogen, alkyl, aryl and non-aromatic heterocyclic groups, or each of one or more pair(s)...
6825217 Carbinols for the treatment of neuropathic dysfunction  
Compositions and methods are provided for treating neuropathic pain or neuropathic dysfunction that include the administration of an effective amount of a defined carbinol or a pharmaceutically...
6825228 Benzothiophene compounds having antiinfective activity  
Benzothiophene compounds such as are DNA binding compounds exhibiting antibacterial activity.
6803370 Alpha amino acid derivatives—inhibitors of leukocyte adhesion mediated by VLA-4  
Disclosed are certain alpha amino acid compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such...
6790463 Uses of targeted oxidative therapeutic formulation in arteriosclerosis  
The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction...
6787559 Sulfonamide compounds  
This invention relates to certain sulfonamide derivatives that are inhibitors of procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use and methods for...
6784167 17-beta-hydroxysteroid dehydrogenase-II inhibitors  
17-beta-hydroxysteroid dehydrogenase-II inhibitors having the structural formula wherein the phenyl group labeled A and the group —C(R 4 )(R 6 )Y are oriented cis to each other; W represents O...
6784173 Aromatic dicarboxylic acid derivatives  
Compounds of formula I wherein A, R 1 and R 2 are defined in the specification. These compounds are useful as HDAC inhibitors. Also disclosed are methods of making and using said compounds.
6777433 Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates  
The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods...
6762182 Converting cox inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors  
A method of altering specificity of cyclooxygenase-inhibiting compounds that have a COOH moiety by changing the various COOH containing compounds, such as indomethacin, into ester derivatives or...
6759412 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents  
The present invention relates to compounds according to the general formula (I), wherein R 1 -R 4 have the meanings given in the description, A is CH 2 , CHOH or CH—(C 1 -C 3 -alkyl), B, C...
6756396 Ethylene glycol esters as photoactive agents  
New compounds useful in photodynamic therapy are of the formula and their 1,4-diene isomers and the metallated and/or labeled and/or conjugated forms thereof wherein each R 1 is independently...
6750213 Estrogen receptor modulators  
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen...
6747054 EP4 receptor selective agonists in the treatment of osteoporosis  
This invention is directed to EP4 receptor selective prostaglandin agonists of the Formula I, wherein R 2 , X, Z and Q are as defined in the specification. This invention is also directed to...
6743810 Indol-3-yl derivatives  
Indol-3-yl derivatives of the general formula I in which A, B, X, R 1 , R 2 , R 3 , R 4 , R 5 , n and m are as defined in patent claim 1 , and their physiologically acceptable salts or solvates...
6740647 Thrombin inhibitors  
Novel five-membered heterocyclic amidines, their preparation and use as competitive inhibitors of trypsin-like serine proteases, especially thrombin and kininogenases such as kallikrein....
6734204 Serotonin potentiation by oleamide analogs  
Analogs related to oleamide are employed for potentiating the 5-HT 2A and 5-HT 1A responses to serotonin (5-HT). With respect to the potentiation of the 5-HT 2A receptor response, it is...
6734206 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure  
The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective...